<DOC>
	<DOCNO>NCT00923468</DOCNO>
	<brief_summary>Background : - A pharmacokinetic ( PK ) study new drug involve take several blood sample period time study participant determine body handle substance . These study provide critical information new drug . - Often , patient parent child drug study choose participate optional PK study part study protocol . - A good understanding patient family agree participate PK study may help researcher make easy people participate . Objectives : - To learn people agree participate PK blood sample study . Eligibility : - Patients 18 year age old parent guardian child participate study drug include option participate PK sample . Design : - Participants fill 2-page survey ask participate study 's PK sampling .</brief_summary>
	<brief_title>Pharmacokinetic Studies Participation Survey</brief_title>
	<detailed_description>Background : Pharmacokinetic study provide critical information disposition anticancer drug child . However , participation child pharmacokinetic portion phase I study optional prospect direct benefit child . The rate participation optional PK study COG Phase I Consortium Studies 60-70 % . There recent data family agree participate optional PK study . Understanding family ' reason may reveal barrier participation could overcome , lead increased participation rate optional PK sampling . Objectives : To use simple 2 page survey gather preliminary information parents/children agree participate Phase I Studies agree participate voluntary pharmacokinetic ( PK ) portion study . Eligibility : Subjects ( great equal 18 year old ) parents/guardians subject minor consent Phase I study optional PK sample previous 4 week . Consent primary Phase I treatment protocol must active ( withdrawn ) . No limit number prior Phase I study subject subject 's child participate . Subjects may participate study . Design : The individual provide consent treatment study include optional PK sample complete short questionnaire . Subjects ( n=50 ) convenience sample complete return questionnaire . Reasons participate agree participate tabulate . Correlations answer subject demographic , time require PK , need additional IV sought . Subjects meet study criterion questionnaire return , lose follow , consent data submission primary treatment protocol withdrawn . The total accrual 50 subject . Accrual ceiling POB , NCI 25 subject .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<criteria>INCLUSION CRITERIA : Subjects consent within 4 week prior enrollment questionnaire study Phase 1 study include optional PK sampling . ( If subject minor parent legally authorize representative provide consent , subject questionnaire study refers parent ) . The PK questionnaire complete within 4 week subject consent study include optional PK sampling . ( Note : The Phase 1 study need COG study ) . Subjects eligible regardless whether initially agree participate PK portion regardless whether actually complete PK sample ( long reason complete sample withdrawal consent ) . Subjects must withdraw consent study include optional PK sampling . Subjects must initially agree optional PK sample withdrawn consent sample prior complete questionnaire . Subjects eligible regardless many phase 1 study enrol past . Each subject may participate survey .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>August 31, 2009</verification_date>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Phase I Trials</keyword>
	<keyword>Children</keyword>
	<keyword>Relaspsed Solid Tumors</keyword>
	<keyword>Relapsed Leukemia</keyword>
	<keyword>Relapsed Brain Tumors</keyword>
</DOC>